Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5553063 | Biomedicine & Pharmacotherapy | 2017 | 11 Pages |
â¢Colebrookea opposotifolia was evaluated against experimental models of epilepsy.â¢The MeCO and AqCO showed significant anticonvulsant activity.â¢MeCO has elevated GABA levels in brain and it was blocked by GABA anatagonist.â¢Thus confirmed the GABA mechanism behind anticonvulsant activity.â¢MeCO has showed Gallic acid, Kaempferol and Coumaric acid in the HPLC analysis
BackgroundColebrookea oppositifolia Smith is one of the commonly used plants to treat epilepsy by various folk medicine communities like nomadic Gujjars, Tharu and Bhoxa in sub-Himalayan regions of India.PurposeThe present study was undertaken to evaluate the anticonvulsant activity of roots of Colebrookea oppositifolia using various experimental models of epilepsy in mice.MethodsPetroleum ether extract of roots of C. Oppositifolia (PeCO), methanolic eCO (MeCO) and aqueous eCO (AeCO) was initially evaluated in six-hertz-seizure test in mice, the effective extract was further evaluated against maximal electroshock (MES) and pentylenetetrazole (PTZ) models in mice. In addition, the potent extract was evaluated against the PTZ model by co-administering with flumazenil (FMZ), and also evaluated for its effect on brain GABA levels in brain and NMDA-induced lethality in mice. Furthermore, the possible locomotor deficit-inducing property of the extract was evaluated by actophotometer test in mice.ResultsIn six-hertz-seizure test the MeCO (25, 50, 100 and 200Â mg/kg) and AeCO (50, 100, 200, 400 and 800Â mg/kg) showed significant protection compared to control group, and MeCO was more potent than AeCO. Based on these outcomes, only MeCO was evaluated in MES and PTZ models. Notably, the MeCO (25, 50, 100 and 200Â mg/kg) has offered significant and dose- dependent protection against MES and PTZ-induced seizures in mice. Alongside, the MeCO (100 and 200Â mg/kg) showed a significant increase in GABA levels in the brain compared to control. In line with these findings, the anti-PTZ effect of MeCO (100Â mg/kg, p.o.) was blocked when co-administered with flumazenil (3Â mg/kg, i.p.),and in NMDA-induced mortality test, the MeCO has shown only 50% protection at 200Â mg/kg dose, thus confirmed the significant role of GABA pathway. Interestingly, the MeCO did not cause significant change in locomotor activity compared to before treatment.ConclusionThese findings suggest that MeCO possess significant anticonvulsant activity and the outcomes further confirmed the involvement of GABAergic mechanisms behind the anticonvulsant activity of MeCO.
Graphical abstractDownload high-res image (177KB)Download full-size image